Innovations in Bottled Water: NPD opportunities in flavored, functional, natural and premium waters

Innovations in Bottled Water: NPD opportunities in flavored, functional, natural and premium waters
  • Report price : $ 1 910
  • Publication date : October 2007
  • Length : 103 pages

Innovations in Bottled Water: NPD opportunities in flavored, functional, natural and premium waters

Between 2006 and 2010 the value of the combined US, European and Japanese bottled water market is projected to see a compound annual growth rate (CAGR) of 5.0%. Volume growth will be healthy at a projected CAGR of 4.7% for the total market. In value terms, Europe is the largest regional market for bottled water and this will remain constant over the period. Of all markets, the UK is projected to see the highest rate of value growth at 8.7%, from $2.4 billion in 2006 to $3.3bn in 2010. The largest single market is the US market, with a value in 2006 of $15.3bn, projected to rise by $4.0bn by 2010. In monetary terms, this represents the greatest value growth, driven by the size of the market and a high projected CAGR rate of 6.0%. The still unflavored water category is the largest of all the bottled water categories. In 2006 the combined markets of Europe, the US and Japan was estimated to be worth $32.4bn. Still unflavored water is also by far the largest bottled water category in terms of volume sales. In 2006, volume sales for this category were estimated at 56.3bn liters. This is projected to rise by 12.1bn liters to a new level of 68.4bn liters in 2010.

RELATED REPORTS

Biomanufacturing Strategies: Market drivers, build-vs-buy decisions and opportunities in contract relationship management

Biomanufacturing Strategies: Market drivers, build-vs-buy decisions and opportunities in contract relationship management

  • $ 2 875
  • September 2007
  • 182 pages

The contract biomanufacturing market achieved a value of $2.5bn in 2006, with growth expected to continue at an annual rate of 0- 5% until at least 20. The proportion of biologics in new drug approvals has risen by over 30% during the last decade, and with the current pipeline containing more than 5 ...

| Countries : USA

Translational Medicine in Biopharmaceutical R&D: Enabling R&D optimization and early detection of potential failures

Translational Medicine in Biopharmaceutical R&D: Enabling R&D optimization and early detection of potential failures

  • $ 2 875
  • October 2007
  • 161 pages

As the pharma industry continues to experience rising research costs, drug failures and low returns on investment, companies who are increasingly facing major patent expiries and scarcely populated late-stage pipelines have accelerated efforts to enhance the speed and efficiency of drug research. T ...

Drug Development Opportunities in China: Regulation, key players and initiatives for domestic and international markets

Drug Development Opportunities in China: Regulation, key players and initiatives for domestic and international markets

  • $ 2 875
  • September 2007
  • 141 pages

Drug developments in the US and EU are becoming increasingly expensive and time consuming, with new products typically requiring investment of over 4 years and $1billion from concept to commercialization. As a result, China has emerged as an increasingly attractive option for companies aiming to red ...

| Countries : USA, China

Immunomodulators: Therapeutic Needs, Pipelines & Prospects

Immunomodulators: Therapeutic Needs, Pipelines & Prospects

  • $ 2 875
  • August 2007
  • 345 pages

The modulation of immune system activity is a required pharmacological intervention for many medical conditions, bearing particular importance in the treatment of autoimmune diseases and allergies and transplant procedures. With traditional immunomodulatory drugs continuing to exhibit limited effica ...

| Countries : USA

The Gastrointestinal Market Outlook to 2012

The Gastrointestinal Market Outlook to 2012

  • $ 2 875
  • October 2007
  • 189 pages

As the GIT Market begins to feature increasingly high levels of generic competition, the focus of pharmaceutical R&D strategies has shifted towards new therapy areas such as Crohn’s disease and Irritable Bowel Syndrome (IBS). Although such shifts are becoming the driving force for market transform ...

Infrastructure Virtualisation: Transforming the Way IT is Delivered

Infrastructure Virtualisation: Transforming the Way IT is Delivered

  • $ 1 869
  • September 2007
  • 220 pages

The convergence of three significant factors in the global economy have created the conditions that make IT virtualisation a technology that will become the dominant technology in data centres within the next two to three years: The need for organisations to reduce its energy consumption, which ena ...

Organon: PharmaVitae Profile

Organon: PharmaVitae Profile

  • $ 5 700
  • October 2007
  • 159 pages

IntroductionThis analysis examines the historical and forecast performance for Organon in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An inte ...

| Countries : USA

Sizing and Forecasting the UK Plastic Card market

Sizing and Forecasting the UK Plastic Card market

  • $ 2 795
  • October 2007
  • 78 pages

IntroductionThis brief is the first section of Datamonitor's ``UK Plastic Cards 2007`` report. In it, the UK plastic card market is sized by the number of cards, as well as the value and number of transactions. Data is segmented by card type. The brief contains a discussion of the drivers of market ...

| Countries : United Kingdom

Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family

Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family

  • $ 7 600
  • October 2007
  • 194 pages

IntroductionDrug targets are the critical link between drugs and their role in the treatment of medical disorders. By grouping drug targets into key protein families, this report provides a comprehensive analysis of the prescription pharmaceutical market by not just molecule type and therapy area, ...

The European Electronic Manufacturing Services Industry 2006-2011

The European Electronic Manufacturing Services Industry 2006-2011

  • $ 2 719
  • August 2007
  • 272 pages

The report covers the strategic issues facing one of the fastest growing sectors of the European electronics industry. In addition to detailed market forecasts by sector and country, the report includes 20 detailed profiles of the major CEMs in Europe and additional information on a further 100 smal ...

| Countries : Morocco, Israel, Bulgaria, Estonia, Hungary, Lithuania, Poland, Czech Republic, Romania, Slovakia, Slovenia, Denmark, Finland, Norway, Sweden, Germany, Austria, Belgium, Spain, France, Ireland, Italy, Malta, Netherlands, Portugal, United Kingdom, Switzerland, Turkey

reportlinker.com © Copyright 2009. All rights reserved

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.